Clinical trials: Urothelial Cancer
Urothelial Cancer
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer.
- Trial name
- EV-302 (NCT04223856)
- Testing
- Enfortumab vedotin, Pembrolizumab, Cisplatin
- Where
- 260 sites in United States, Argentina and 23 more
- Volunteers
- 886 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Bladder (Urothelial, Transitional Cell) Cancer
Observational Clinical Study of Patients With Muscle - Invasive Bladder Cancer Undergoing Bladder Preservation Therapy After Neoadjuvant Therapy
The goal of this observational study is to evaluate the safety and efficacy of neoadjuvant therapy followed by bladder - preserving TMT in patients with MIBC.
- Trial name
- NCT07053722
- Testing
- NA-TMT
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
Neoplasms
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive…
- Trial name
- NCT02635672
- Testing
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda
- Where
- 16 sites in United States, Chile and 1 more
- Volunteers
- 110 people
- Sponsor
- Vincerx Pharma, Inc.
Solid Tumor, Urethral Cancer
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
The goal of this clinical research study is to find the highest tolerable dose of Gemzar® (gemcitabine) and Adriamycin® (doxorubicin) that can be given together with Velcade® (bortezomib) in patients with urothelial cancer or…
- Trial name
- NCT00479128
- Testing
- Bortezomib, Gemcitabine, Doxorubicin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer, Urothelial Carcinoma
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
In this phase I first-in-humans-study a vaccine consisting of arginase-1 (ARG1) peptides and the adjuvant Montanide ISA-51 will be tested in ten patients with metastatic solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Urothelial Carcinoma, Malignant Melanoma, Ovarian Cancer
- Trial name
- NCT03689192
- Testing
- ARG1-18,19,20
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Herlev Hospital
Advanced Urothelial Carcinoma
Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer
Patients with metastatic bladder cancer are usually treated with chemotherapy. If their cancers do not progress after chemotherapy, they can be enrolled into this study and receive a standard-of-care immunotherapy medication…
- Trial name
- NCT05687721
- Testing
- copanlisib, Avelumab
- Where
- United States
- Sponsor
- VA Office of Research and Development
Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
This phase II trial studies how well atezolizumab when given with glycosylated recombinant human interleukin-7 (CYT107) works in treating patients with urothelial carcinoma that has spread to nearby tissue or lymph nodes (locally…
- Conditions
- Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma
- Trial name
- NCT03513952
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
This is a Phase 1/2, open-label, dose-exploration, combination/expansion study, which will start by evaluating the safety and tolerability of NTX-301, an oral DNMT1 inhibitor, as a monotherapy in patients with advanced solid…
- Conditions
- Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Urothelial Carcinoma, High-grade Glioma
- Trial name
- NCT04851834
- Testing
- NTX-301, Platinum-based Chemotherapy, Temozolomide
- Where
- 2 sites in Australia
- Volunteers
- 12 people
- Sponsor
- Xennials Therapeutics Australia Pty Ltd
Bladder Cancer
A Study of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial Cancer
This ambispective (both retrospective and prospective) NIS will evaluate the effectiveness and safety of Avelumab as a maintenance therapy administered after completion of first-line platinum-based chemotherapy in patients with…
- Trial name
- NCT05568407
- Testing
- Avelumab
- Where
- 7 sites in Argentina, Brazil
- Volunteers
- 19 people
- Sponsor
- Pfizer
Urothelial Carcinoma
Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma
The purpose of this study is to explore the safety and activity of docetaxel + ASA404 as second-line chemotherapy in patients with advanced urothelial carcinoma.
- Trial name
- NCT01071928
- Testing
- Docetaxel, ASA404
- Sponsor
- Hoosier Cancer Research Network
Metastatic Urothelial Carcinoma, Breast Cancer
Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.
- Conditions
- Metastatic Urothelial Carcinoma, Breast Cancer, TNBC - Triple-Negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
- Trial name
- NCT07671092
- Testing
- RYZ211/212
- Where
- 6 sites in Australia, New Zealand and 1 more
- Volunteers
- 40 people
- Sponsor
- RayzeBio, Inc.
Solid Tumors, Triple Negative Breast Cancer (TNBC)
A Study of ADRX-0706 in Select Advanced Solid Tumors
The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.
- Conditions
- Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
- Trial name
- NCT06036121
- Testing
- ADRX-0706
- Where
- 21 sites in United States, China
- Volunteers
- 144 people
- Sponsor
- Adcentrx Therapeutics
Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
This phase II trial tests how well CPI-613 (devimistat) in combination with hydroxychloroquine (HCQ) and 5-fluorouracil (5-FU) or gemcitabine works in patients with solid tumors that may have spread from where they first started…
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Adenocarcinoma
- Trial name
- NCT05733000
- Testing
- Biospecimen Collection, Computed Tomography, Devimistat
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Northwestern University
Urothelial Carcinoma
Immunotherapy in Upper Tract Urothelial Carcinoma
Upper-tract urothelial carcinoma (UTUC) is a rare tumor. Standard treatment of localized disease is most often radical nephroureterectomy.
- Trial name
- VESUVIO (NCT06113367)
- Testing
- Evaluation of anti-PD-(L)1 immunotherapy efficacy
- Volunteers
- 350 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors.
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03228667
- Testing
- N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab
- Where
- 35 sites in United States
- Volunteers
- 40 people
- Sponsor
- ImmunityBio, Inc.
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium
RATIONALE: Drugs used in chemotherapy, such as ifosfamide, doxorubicin, gemcitabine, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00080795
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy.
- Trial name
- TroFuse-031 (NCT07419295)
- Testing
- Sacituzumab tirumotecan, Vinflunine, Docetaxel
- Where
- 107 sites in United States, Argentina and 15 more
- Volunteers
- 590 people
- Sponsor
- Merck Sharp & Dohme LLC
Urinary Bladder Neoplasms, Neoplasm Metastasis
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other medicines that treat cancer.
- Conditions
- Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
- Trial name
- FORAGER-1 (NCT05614739)
- Testing
- Vepugratinib, Pembrolizumab, enfortumab vedotin
- Where
- 82 sites in United States, Australia and 12 more
- Volunteers
- 677 people
- Sponsor
- Eli Lilly and Company
Melanoma, NSCLC
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Patients with histologically or cytologically confirmed advanced melanoma, renal cell carcinoma, NSCLC, HCC (Child Pugh Class A only), MSI-High solid tumors, Urothelial Cancer, GE junction/Gastric Adenocarcinoma, or HNSCC for…
- Conditions
- Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer
- Trial name
- NCT04114136
- Testing
- Nivolumab or Pembrolizumab (dependent upon approved indication), Metformin, Rosiglitazone
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Dan Zandberg
Urothelial Carcinoma, Urethral Neoplasms
Cabozantinib for Advanced Urothelial Cancer
Background: Cabozantinib is a drug that slows the growth of blood vessels that feed tumors. It is approved for medullary thyroid cancer. However, studies have shown that prostate and ovarian tumors respond to it.
- Conditions
- Urothelial Carcinoma, Urethral Neoplasms, Urinary Bladder Neoplasms, Kidney Neoplasms
- Trial name
- NCT01688999
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.